(NDSN) Nordson - Overview

Sector: Industrials | Industry: Specialty Industrial Machinery | Exchange: NASDAQ (USA) | Market Cap: 15.723m USD | Total Return: 38.6% in 12m

Adhesive Dispensers, Medical Components, Inspection Systems, Coating Equipment

Total Rating 66

Safety 82

Buy Signal -0.12

Specialty Industrial Machinery
Industry Rotation: -5.9

Market Cap: 15.7B
Avg Turnover: 81.7M

Risk 3d forecast

Volatility23.3%

VaR 5^th Pctl3.77%

VaR vs Median-1.81%

Reward TTM

Sharpe Ratio1.43

Rel. Str. IBD65.5

Rel. Str. Peer Group65.1

Character TTM

Beta1.059

Beta Downside1.238

Hurst Exponent0.506

Drawdowns 3y

Max DD39.15%

CAGR/Max DD0.25

CAGR/Mean DD0.83

EPS (Earnings per Share)

EPS CAGR: -0.66%
EPS Trend: 34.0%

Last SUE: 0.00
Qual. Beats: 0

Revenue

Rev. CAGR: 1.40%
Rev. Trend: 46.8%

Last SUE: 1.23
Qual. Beats: 1

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: NDSN Nordson

Nordson Corporation (NDSN) is an Ohio-based industrial technology firm specializing in precision dispensing, fluid management, and quality control systems. The company operates through three primary segments-Industrial Precision Solutions, Medical and Fluid Solutions, and Advanced Technology Solutions-serving diverse end markets including consumer non-durables, medical device manufacturing, and electronics.

The business model relies heavily on a razor-and-blade strategy, where the installation of complex, proprietary dispensing systems generates recurring revenue through the sale of specialized consumables, replacement parts, and maintenance services. This high-margin aftermarket component typically provides a buffer against cyclical fluctuations in capital equipment spending.

Within the semiconductor and electronics sectors, Nordsons automated optical and X-ray inspection systems are critical for ensuring the structural integrity of printed circuit boards and advanced packaging. As global manufacturing shifts toward miniaturization and increased automation, the demand for high-speed, sub-micron fluid application continues to expand. Further exploration of these market trends on ValueRay can provide deeper context for the companys valuation.

Founded in 1909, Nordson maintains a global footprint, utilizing a mix of direct sales and specialized distributors to reach international markets. Its medical segment focuses on high-growth areas such as interventional delivery systems and biomaterial dispensing, positioning the firm within the specialized medical component manufacturing supply chain.

Headlines to Watch Out For

Semiconductor and electronics demand volatility impacts Advanced Technology Solutions revenue
Medical segment growth depends on surgical procedure volumes and interventional device adoption
Industrial Precision Solutions margins fluctuate with global manufacturing and packaging activity
Strategic acquisitions and integration efficiency drive long-term earnings and inorganic growth
Raw material costs and global supply chain stability affect manufacturing profitability

Piotroski VR‑10 (Strict) 8.5

Net Income: 523.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA 2.93 > 1.0
NWC/Revenue: 27.82% < 20% (prev 27.77%; Δ 0.05% < -1%)
CFO/TA 0.12 > 3% & CFO 700.5m > Net Income 523.2m
Net Debt (2.02b) to EBITDA (913.9m): 2.21 < 3
Current Ratio: 2.72 > 1.5 & < 3
Outstanding Shares: last quarter (56.1m) vs 12m ago -2.36% < -2%
Gross Margin: 55.17% > 18% (prev 0.55%; Δ 5.46k% > 0.5%)
Asset Turnover: 48.10% > 50% (prev 45.51%; Δ 2.59% > 0%)
Interest Coverage Ratio: 6.41 > 6 (EBITDA TTM 913.9m / Interest Expense TTM 119.2m)

Altman Z'' 6.01

A: 0.13 (Total Current Assets 1.25b - Total Current Liabilities 460.0m) / Total Assets 5.96b
B: 0.79 (Retained Earnings 4.69b / Total Assets 5.96b)
C: 0.13 (EBIT TTM 763.8m / Avg Total Assets 5.92b)
D: 1.63 (Book Value of Equity 4.64b / Total Liabilities 2.85b)
Altman-Z'' Score: 6.01 = AAA

Beneish M -3.00

DSRI: 1.01 (Receivables 571.6m/531.3m, Revenue 2.85b/2.67b)
GMI: 1.00 (GM 55.17% / 55.15%)
AQI: 1.01 (AQ_t 0.69 / AQ_t-1 0.68)
SGI: 1.06 (Revenue 2.85b / 2.67b)
TATA: -0.03 (NI 523.2m - CFO 700.5m) / TA 5.96b)
Beneish M-Score: -3.00 (Cap -4..+1) = A

What is the price of NDSN shares? As of May 17, 2026, the stock is trading at USD 274.88 with a total of 613,600 shares traded.
Over the past week, the price has changed by -3.05%, over one month by -0.04%, over three months by -7.14% and over the past year by +38.60%.

Is NDSN a buy, sell or hold? Nordson has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy NDSN.

StrongBuy: 5
Buy: 2
Hold: 3
Sell: 0
StrongSell: 0

What are the forecasts/targets for the NDSN price?

Analysts Target Price	310.5	13%

Nordson (NDSN) - Fundamental Data Overview as of 14 May 2026

P/E Trailing = 30.5032
P/E Forward = 24.57
P/S = 5.525
P/B = 5.0822
P/EG = 1.9046
Revenue TTM = 2.85b USD
EBIT TTM = 763.8m USD
EBITDA TTM = 913.9m USD
Long Term Debt = 1.94b USD (from longTermDebt, last quarter)
Short Term Debt = 76.5m USD (from shortTermDebt, last quarter)
Debt = 2.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.02b USD (from netDebt column, last quarter)
Enterprise Value = 17.74b USD (15.72b + Debt 2.14b - CCE 120.4m)
Interest Coverage Ratio = 6.41 (Ebit TTM 763.8m / Interest Expense TTM 119.2m)
EV/FCF = 27.45x (Enterprise Value 17.74b / FCF TTM 646.3m)
FCF Yield = 3.64% (FCF TTM 646.3m / Enterprise Value 17.74b)
FCF Margin = 22.71% (FCF TTM 646.3m / Revenue TTM 2.85b)
Net Margin = 18.39% (Net Income TTM 523.2m / Revenue TTM 2.85b)
Gross Margin = 55.17% ((Revenue TTM 2.85b - Cost of Revenue TTM 1.28b) / Revenue TTM)
Gross Margin QoQ = 54.69% (prev 56.33%)
Tobins Q-Ratio = 2.98 (Enterprise Value 17.74b / Total Assets 5.96b)
Interest Expense / Debt = 1.25% (Interest Expense 26.8m / Debt 2.14b)
Taxrate = 18.92% (31.1m / 164.5m)
NOPAT = 619.3m (EBIT 763.8m * (1 - 18.92%))
Current Ratio = 2.72 (Total Current Assets 1.25b / Total Current Liabilities 460.0m)
Debt / Equity = 0.69 (Debt 2.14b / totalStockholderEquity, last quarter 3.11b)
Debt / EBITDA = 2.21 (Net Debt 2.02b / EBITDA 913.9m)
Debt / FCF = 3.13 (Net Debt 2.02b / FCF TTM 646.3m)
Total Stockholder Equity = 3.02b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.84% (Net Income 523.2m / Total Assets 5.96b)
RoE = 17.30% (Net Income TTM 523.2m / Total Stockholder Equity 3.02b)
RoCE = 15.38% (EBIT 763.8m / Capital Employed (Equity 3.02b + L.T.Debt 1.94b))
RoIC = 12.13% (NOPAT 619.3m / Invested Capital 5.11b)
WACC = 8.67% (E(15.72b)/V(17.86b) * Re(9.71%) + D(2.14b)/V(17.86b) * Rd(1.25%) * (1-Tc(0.19)))
Discount Rate = 9.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -67.42 | Cagr: -1.11%
[DCF] Terminal Value 77.73% ; FCFF base≈573.7m ; Y1≈642.5m ; Y5≈854.9m
[DCF] Fair Price = 200.2 (EV 13.19b - Net Debt 2.02b = Equity 11.17b / Shares 55.8m; r=8.67% [WACC]; 5y FCF grow 13.88% → 3.0% )
EPS Correlation: 33.97 | EPS CAGR: -0.66% | SUE: 0.0 | # QB: 0
Revenue Correlation: 46.78 | Revenue CAGR: 1.40% | SUE: 1.23 | # QB: 1
EPS current Quarter (2026-07-31): EPS=3.06 | Chg30d=+0.76% | Revisions=+20% | Analysts=8
EPS current Year (2026-10-31): EPS=11.45 | Chg30d=-0.06% | Revisions=-20% | GrowthEPS=+11.8% | GrowthRev=+5.6%
EPS next Year (2027-10-31): EPS=12.34 | Chg30d=+0.27% | Revisions=-20% | GrowthEPS=+7.8% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: +20%